77541-65-2

Usage

Uses

Used in Pharmaceutical Industry:
2-BENZYL-5-CHLORO-4-METHOXY-3(2H)-PYRIDAZINONE is used as an antimicrobial and antifungal agent for its ability to inhibit the growth of a broad spectrum of bacteria and fungi. This makes it a valuable asset in the development of treatments for various skin infections and other conditions caused by microbial pathogens.
Used in Skin Infection Treatments:
In the dermatological field, 2-BENZYL-5-CHLORO-4-METHOXY-3(2H)-PYRIDAZINONE is utilized as a therapeutic agent for treating skin infections. Its potential to combat a wide range of bacteria and fungi contributes to its effectiveness in managing and alleviating symptoms associated with such infections.
Used in Research and Development:
2-BENZYL-5-CHLORO-4-METHOXY-3(2H)-PYRIDAZINONE is also used as a subject of research for further exploration of its antimicrobial and antifungal properties. This research aims to enhance our understanding of its mechanism of action, optimize its efficacy, and potentially discover new applications in medicine.
Used in Drug Formulation:
In the development of new drugs, 2-BENZYL-5-CHLORO-4-METHOXY-3(2H)-PYRIDAZINONE is considered as an active pharmaceutical ingredient for the formulation of medications designed to combat microbial infections. Its incorporation into drug products can lead to the creation of novel therapies that address the growing need for effective antimicrobial and antifungal treatments.

InChI:InChI=1/C12H11ClN2O2/c1-17-11-10(13)7-14-15(12(11)16)8-9-5-3-2-4-6-9/h2-7H,8H2,1H3

Upstream product

• 41933-33-9 2-benzyl-4,5-dichloro-3(2H)-pyridazinone 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 124-41-4 sodium methylate 

Downstream Products

• 856250-30-1 2-benzyl-5-(4-chlorophenyl)-4-methoxypyridazin-3(2H)-one 
• 476171-99-0 3-benzyl-pyridazino[4,5-c]isoquinolin-4(3H)-one 
• 938045-24-0 2-benzylbenzo[f]phthalazin-1(2H)-one 
• 938045-23-9 2-benzyl-4-(2-formylphenyl)-5-methylpyridazin-3(2H)-one 
• 938045-33-1 C₁₂H₁₁CF₃SO₂N₂O₂ 
• 938045-22-8 2-benzyl-4-hydroxy-5-methylpyridazin-3(2H)-one 
• 938045-21-7 2-benzyl-4-methoxy-5-methylpyridazin-3(2H)-one 
• 476171-97-8 2-(1-benzyl-5-methoxy-6-oxo-1,6-dihydropyridazin-4-yl)benzaldehyde 

Relevant academic research and scientific papers

Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat

The design and synthesis of two closely related series of prostacyclin receptor agonist compounds that showed excellent human IP receptor potency and efficacy is described. Compounds from this series showed in vivo activity after SC dosing in the monocrotaline model of PAH in rat.

Azabicyclic heterocycles as cannabinoid receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I and Formula II: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3 and R4 are described herein.

Macrocyclic hepatitis C serine protease inhibitors

The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Azabicyclic heterocycles as cannabinoid receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.

Synthesis of 4-aryl-5-hydroxy- and 5-aryl-4-hydroxypyridazin-3(2H)-ones and their use in the preparation of 4,5-diarylpyridazin-3(2H)-ones and hitherto unknown isochromeno[3,4-d]pyridazinediones

Easily accessible 2-substituted 4-aryl-5-methoxy- and 2-substituted 5-aryl-4-methoxypyridazin-3(2H)-ones were transformed into the corresponding aryl-hydroxypyridazin-3(2H)-ones by alkaline hydrolysis. The use of these compounds in the synthesis of 2-substituted 4,5-diarylpyridazin-3(2H)-ones with two differently substituted aryl groups was investigated. Two aryl-hydroxypyridazin-3(2H)-ones, 2-(2-benzyl-5-hydroxy-3-oxo-2,3-dihydropyridazin-4-yl)benzaldehyde and 2-(1-benzyl-5-hydroxy-6-oxo-1,6-dihydropyridazin-4-yl)benzaldehyde, were transformed into 2-benzyl-1H-isochromeno[3,4-d]pyridazine-1,6(2H)-dione and 3-benzyl-3H-isochromeno[3,4-d]pyridazine-4,6-dione, respectively, via oxidation of the formyl group with KMnO4 followed by lactonization.

Synthesis of new pyridazino[4,5-c]isoquinolinones by Suzuki cross-coupling reaction

Suzuki cross-coupling reaction of 2-alkyl(methyl and benzyl)-5-chloro-4-methoxy- and 2-alkyl(methyl and benzyl)-4-chloro-5-methoxypyridazin-3(2H)-ones with 2-formylphenylboronic acid afforded the corresponding biaryl products which were cyclized with ammonia to yield hitherto undescribed pyridazino[4,5-c]isoquinolinones. Removal of the N-benzyl protective group in position 2 yielded the unsubstituted tricyclic pyridazinones.